Kura Oncology science chief exercises 30,000 options

The reported option was fully vested, carried a $6.15 exercise price and had a January 22, 2027 expiration date.

Rhea-AI Filing Summary

Kura Oncology, Inc. Chief Scientific Officer Burrows Francis exercised 30,000 fully vested stock options on September 24, 2026, at an exercise price of $6.15 per share, acquiring 30,000 common shares. He sold 20,726 shares that day at a weighted average price of $10.8325 per share. The transaction was described as a cashless exercise and sale of a portion to cover estimated payroll tax liability; the sale trades ranged from $10.82 to $10.85. The option row reported 0 options following the transaction and an expiration date of January 22, 2027.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 3 txns

Insider Burrows Francis

Role Chief Scientific Officer

Sold 20,726 shs ($225K)

Approx. gross sale proceeds $225K

Approx. exercise cost $185K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) F4	30,000	$0.00	$0.00
Exercise	Common Stock F1, F2	30,000	$6.15	$185K
Sale	Common Stock F3	20,726	$10.8325	$225K

Holdings After Transaction: Stock Option (Right to Buy) — 0 contracts (Direct); Common Stock — 42,327 shares (Direct)

Footnotes (4)

1. F1. Cashless exercise and sale of a portion of a stock option to cover estimated payroll tax liability.
2. F2. Includes 629 shares acquired on May 17, 2026 pursuant to the Issuer's Employee Stock Purchase Plan.
3. F3. This transaction was executed in multiple trades at prices ranging from $10.82 to $10.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
4. F4. This option is fully vested.

Key Figures

Options exercised: 30,000 options Exercise price: $6.15 per share Shares sold: 20,726 shares +3 more

6 metrics

Options exercised 30,000 options September 24, 2026

Exercise price $6.15 per share Options exercised September 24, 2026

Shares sold 20,726 shares September 24, 2026

Weighted average sale price $10.8325 per share Sale on September 24, 2026

Sale price range $10.82 to $10.85 per share Multiple trades on September 24, 2026

Options following transaction 0 options Reported after the September 24, 2026 exercise

Key Terms

cashless exercise, weighted average sale price, fully vested

3 terms

cashless exercise financial

"Cashless exercise and sale of a portion of a stock option"

A cashless exercise is a way for an option holder to convert stock options into actual shares without paying the purchase price in cash; instead they immediately give up a portion of the newly issued shares to cover the cost and any withholding taxes. Investors care because this process increases the number of shares available and can slightly dilute existing holdings, while also signaling how insiders or employees are realizing compensation without needing cash — similar to paying for a purchase by handing over part of what you just bought.

weighted average sale price financial

"reflects the weighted average sale price"

fully vested financial

"This option is fully vested"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many options did KURA's Chief Scientific Officer exercise?

Kura Oncology Chief Scientific Officer Burrows Francis exercised 30,000 stock options on September 24, 2026, at an exercise price of $6.15 per share.

What price range did KURA's CSO receive for the shares sold?

The 20,726 shares were sold in multiple trades at prices ranging from $10.82 to $10.85 per share. The reported weighted average sale price was $10.8325 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/25/2026 - 04:18 PM Accepted by SEC EDGAR 09/25/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Burrows Francis

(Last) (First) (Middle)

C/O KURA ONCOLOGY, INC.

4930 DIRECTORS PLACE, SUITE 500

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kura Oncology, Inc. [ KURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/24/2026		M(1)		30,000	A	$6.15	63,053(2)	D
Common Stock	09/24/2026		S		20,726	D	$10.8325(3)	42,327	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$6.15	09/24/2026		M			30,000	(4)	01/22/2027	Common stock	30,000	$0	0	D

Explanation of Responses:

1. Cashless exercise and sale of a portion of a stock option to cover estimated payroll tax liability.

2. Includes 629 shares acquired on May 17, 2026 pursuant to the Issuer's Employee Stock Purchase Plan.

3. This transaction was executed in multiple trades at prices ranging from $10.82 to $10.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

4. This option is fully vested.

	Teresa Bair, Attorney-in-fact for Francis Burrows	09/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)